Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of PA9159 nasal spray in seasonal allergic rhinitis
CTR20260750Phase 2Active
- Sponsor
- Anhui Bolatu Pharmaceutical Technology
- Start
- Feb 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of pa9159 in seasonal allergic rhinitis (SAR) and perennial rhinitis (3 arms), sponsored by Anhui Bolatu Pharmaceutical Technology. Primary endpoint: Change from baseline in average reflective total nasal symptom score. Started Feb 2026; status: active.
02
Drugs
pa9159
03
Conditions
seasonal allergic rhinitis (SAR)perennial rhinitis
Beyond the preview
Go deeper on CTR20260750.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260750.